prednisone and Peripheral Nerve Diseases studies

Prednisone: A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver.
prednisone : A synthetic glucocorticoid drug that is particularly effective as an immunosuppressant, and affects virtually all of the immune system. Prednisone is a prodrug that is converted by the liver into prednisolone (a beta-hydroxy group instead of the oxo group at position 11), which is the active drug and also a steroid.

Research Excerpts

Excerpt	Relevance	Reference
"The usefulness of pharmacokinetics of bortezomib for multiple myeloma (MM) with respect to the maximum response to bortezomib and bortezomib-induced peripheral neuropathy (BIPN) development was studied."	9.24	Bortezomib pharmacokinetics in tumor response and peripheral neuropathy in multiple myeloma patients receiving bortezomib-containing therapy. ( Choi, K; Han, S; Hong, T; Lee, J; Lee, SE; Min, CK; Park, GJ; Yim, DS, 2017)
"Bortezomib and thalidomide significantly improved OS in multiple myeloma patients not eligible for transplantation."	9.19	Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: updated follow-up and improved survival. ( Benevolo, G; Boccadoro, M; Bringhen, S; Cavo, M; Di Raimondo, F; Falcone, AP; Franceschini, L; Gaidano, G; Gottardi, D; Grasso, M; Guglielmelli, T; Larocca, A; Levi, A; Magarotto, V; Marasca, R; Mina, R; Montefusco, V; Morabito, F; Musto, P; Nozzoli, C; Offidani, M; Omedé, P; Palumbo, A; Passera, R; Patriarca, F; Petrucci, MT; Ria, R; Rossi, D; Vincelli, ID; Zambello, R, 2014)
"This subanalysis of the phase 3 VISTA trial aimed to assess the frequency, characteristics and reversibility of, and prognostic factors for, bortezomib-associated peripheral neuropathy (PN) in newly diagnosed patients with multiple myeloma ineligible for high-dose therapy who received bortezomib plus melphalan-prednisone."	9.15	Risk factors for, and reversibility of, peripheral neuropathy associated with bortezomib-melphalan-prednisone in newly diagnosed patients with multiple myeloma: subanalysis of the phase 3 VISTA study. ( Cakana, A; Deraedt, W; Dimopoulos, MA; Esseltine, DL; Khuageva, NK; Kropff, M; Liu, K; Mateos, MV; Palumbo, A; Richardson, PG; San Miguel, JF; Schlag, R; Shpilberg, O; Spicka, I; Van De Velde, H; Wu, KL, 2011)
"A study was undertaken adding the alkylating agent sensitizer etanidazole to intravenous melphalan and oral prednisone for patients with multiple myeloma."	9.07	Use of the hypoxic cell sensitizer etanidazole (SR-2508) with intravenous melphalan and prednisone in the treatment of multiple myeloma: a pharmacokinetic study. ( Buswell, L; Coleman, CN; Kalish, LA; Shulman, LN, 1994)
"We retrospectively investigated the efficacy and predictive factors for the treatment outcomes of bortezomib plus dexamethasone (BD) as second-line induction therapy prior to high-dose chemotherapy supported by autologous stem cell transplantation (HDT/ASCT) in multiple myeloma (MM) patients."	7.79	The response to second-line induction with bortezomib and dexamethasone is predictive of long-term outcomes prior to high-dose chemotherapy with autologous stem cell transplantation for multiple myeloma. ( Akaogi, T; Fuchida, S; Hatsuse, M; Horiike, S; Iwai, T; Kamitsuji, Y; Kaneko, H; Kawata-Iida, E; Kobayashi, T; Kobayashi, Y; Kuroda, J; Matsumoto, Y; Murakami, S; Nakao, M; Okano, A; Shimazaki, C; Shimizu, D; Takahashi, R; Taniwaki, M; Tsutsumi, Y; Uchiyama, H; Uoshima, N, 2013)
"The aim of the study was to evaluate thalidomide as rescue therapy for pediatric patients with severe refractory Crohn disease (CD) who failed to respond to antitumor necrosis factor (TNF) biologic agents."	7.78	Thalidomide use and outcomes in pediatric patients with Crohn disease refractory to infliximab and adalimumab. ( Felipez, LM; Gokhale, R; Kirschner, BS; Tierney, MP, 2012)
"When performing R-CHOP(rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone)for diffuse large B-cell lymphoma(DLBCL), neurotoxicity of vincristine(VCR)is the serious dose-limiting factor."	7.78	[A case of neurotoxicity reduced with pregabalin in R-CHOP chemotherapy for diffuse large B-cell lymphoma]. ( Hosokawa, A; Ito, T; Kiba, T; Kido, M; Kimura, A; Kozawa, K; Nakashima, T; Niimi, H; Ogawa, Y; Okada, Y; Okikawa, Y; Saito, A; Shintani, H; Taniguchi, T; Taniyama, K, 2012)
"Three cases of multiple myeloma treated with thalidomide are presented which highlight therapeutic dilemmas presented by therapy with this new agent."	7.71	Therapeutic dilemmas with thalidomide in multiple myeloma: case discussions. ( Desikan, RK; Jagannath, S, 2001)
"excellent tolerance and efficacy of combined zidovudine and plasmapheresis therapy in peripheral neurological HIV-related vasculitis."	7.68	Successful treatment of HIV-related vasculitis with peripheral neuropathy with short-term steroids followed by the association of zidovudine and plasmapheresis. ( Cohen, P; Gayraud, M; Gherardi, R; Guillevin, L; Jarrousse, B; Leon, A; Lhote, F, 1993)
" Nonhematologic grade 3/4 adverse events were reported in 35% of once-weekly patients and 51% of twice-weekly patients (P = ."	6.75	Efficacy and safety of once-weekly bortezomib in multiple myeloma patients. ( Benevolo, G; Boccadoro, M; Bringhen, S; Callea, V; Cangialosi, C; Cavalli, M; Cavo, M; De Rosa, L; Evangelista, A; Falcone, AP; Gaidano, G; Gentili, S; Genuardi, M; Grasso, M; Guglielmelli, T; Larocca, A; Levi, A; Liberati, AM; Musto, P; Nozzoli, C; Palumbo, A; Patriarca, F; Ria, R; Rizzo, V; Rossi, D, 2010)
"The usefulness of pharmacokinetics of bortezomib for multiple myeloma (MM) with respect to the maximum response to bortezomib and bortezomib-induced peripheral neuropathy (BIPN) development was studied."	5.24	Bortezomib pharmacokinetics in tumor response and peripheral neuropathy in multiple myeloma patients receiving bortezomib-containing therapy. ( Choi, K; Han, S; Hong, T; Lee, J; Lee, SE; Min, CK; Park, GJ; Yim, DS, 2017)
"Bortezomib and thalidomide significantly improved OS in multiple myeloma patients not eligible for transplantation."	5.19	Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: updated follow-up and improved survival. ( Benevolo, G; Boccadoro, M; Bringhen, S; Cavo, M; Di Raimondo, F; Falcone, AP; Franceschini, L; Gaidano, G; Gottardi, D; Grasso, M; Guglielmelli, T; Larocca, A; Levi, A; Magarotto, V; Marasca, R; Mina, R; Montefusco, V; Morabito, F; Musto, P; Nozzoli, C; Offidani, M; Omedé, P; Palumbo, A; Passera, R; Patriarca, F; Petrucci, MT; Ria, R; Rossi, D; Vincelli, ID; Zambello, R, 2014)
"This subanalysis of the phase 3 VISTA trial aimed to assess the frequency, characteristics and reversibility of, and prognostic factors for, bortezomib-associated peripheral neuropathy (PN) in newly diagnosed patients with multiple myeloma ineligible for high-dose therapy who received bortezomib plus melphalan-prednisone."	5.15	Risk factors for, and reversibility of, peripheral neuropathy associated with bortezomib-melphalan-prednisone in newly diagnosed patients with multiple myeloma: subanalysis of the phase 3 VISTA study. ( Cakana, A; Deraedt, W; Dimopoulos, MA; Esseltine, DL; Khuageva, NK; Kropff, M; Liu, K; Mateos, MV; Palumbo, A; Richardson, PG; San Miguel, JF; Schlag, R; Shpilberg, O; Spicka, I; Van De Velde, H; Wu, KL, 2011)
"A study was undertaken adding the alkylating agent sensitizer etanidazole to intravenous melphalan and oral prednisone for patients with multiple myeloma."	5.07	Use of the hypoxic cell sensitizer etanidazole (SR-2508) with intravenous melphalan and prednisone in the treatment of multiple myeloma: a pharmacokinetic study. ( Buswell, L; Coleman, CN; Kalish, LA; Shulman, LN, 1994)
"We retrospectively investigated the efficacy and predictive factors for the treatment outcomes of bortezomib plus dexamethasone (BD) as second-line induction therapy prior to high-dose chemotherapy supported by autologous stem cell transplantation (HDT/ASCT) in multiple myeloma (MM) patients."	3.79	The response to second-line induction with bortezomib and dexamethasone is predictive of long-term outcomes prior to high-dose chemotherapy with autologous stem cell transplantation for multiple myeloma. ( Akaogi, T; Fuchida, S; Hatsuse, M; Horiike, S; Iwai, T; Kamitsuji, Y; Kaneko, H; Kawata-Iida, E; Kobayashi, T; Kobayashi, Y; Kuroda, J; Matsumoto, Y; Murakami, S; Nakao, M; Okano, A; Shimazaki, C; Shimizu, D; Takahashi, R; Taniwaki, M; Tsutsumi, Y; Uchiyama, H; Uoshima, N, 2013)
"The aim of the study was to evaluate thalidomide as rescue therapy for pediatric patients with severe refractory Crohn disease (CD) who failed to respond to antitumor necrosis factor (TNF) biologic agents."	3.78	Thalidomide use and outcomes in pediatric patients with Crohn disease refractory to infliximab and adalimumab. ( Felipez, LM; Gokhale, R; Kirschner, BS; Tierney, MP, 2012)
"When performing R-CHOP(rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone)for diffuse large B-cell lymphoma(DLBCL), neurotoxicity of vincristine(VCR)is the serious dose-limiting factor."	3.78	[A case of neurotoxicity reduced with pregabalin in R-CHOP chemotherapy for diffuse large B-cell lymphoma]. ( Hosokawa, A; Ito, T; Kiba, T; Kido, M; Kimura, A; Kozawa, K; Nakashima, T; Niimi, H; Ogawa, Y; Okada, Y; Okikawa, Y; Saito, A; Shintani, H; Taniguchi, T; Taniyama, K, 2012)
"Three cases of multiple myeloma treated with thalidomide are presented which highlight therapeutic dilemmas presented by therapy with this new agent."	3.71	Therapeutic dilemmas with thalidomide in multiple myeloma: case discussions. ( Desikan, RK; Jagannath, S, 2001)
"excellent tolerance and efficacy of combined zidovudine and plasmapheresis therapy in peripheral neurological HIV-related vasculitis."	3.68	Successful treatment of HIV-related vasculitis with peripheral neuropathy with short-term steroids followed by the association of zidovudine and plasmapheresis. ( Cohen, P; Gayraud, M; Gherardi, R; Guillevin, L; Jarrousse, B; Leon, A; Lhote, F, 1993)
" This prospective cohort study investigated orofacial complications of combination chemotherapy (cyclophosphamide, methotrexate, fluorouracil, vincristine, and prednisone) in women with breast cancer."	3.68	Orofacial complications of chemotherapy for breast cancer. ( McCarthy, GM; Skillings, JR, 1992)
"A young man with dermatitis herpetiformis developed fatigue and neurologic complaints 4 years after he began oral dapsone therapy."	3.67	Dapsone-induced peripheral neuropathy. ( Ahrens, EM; Callen, JP; Meckler, RJ, 1986)
"Subacute polyneuropathy that responded to prednisone was the initial symptom in two patients, one of whom was later found to have histiocytic lymphoma and the other, chronic lymphocytic leukemia."	3.66	Lymphoma and leukemia manifested by steroid-responsive polyneuropathy. ( Farrell, DF; Knauss, TA; Sumi, SM, 1983)
"A woman, aged 58, who had undergone prolonged treatment with corticosteroids for generalized necrotizing vasculitis, and had received azathioprine (Imurel) for 18 months, 4 years after discontinuing the latter treatment, developed peripheral neuropathy and a rapidly progressing cerebral disorder suggesting a basal meningeal process."	3.66	Primary malignant lymphoma of the CNS and polyneuropathy in a patient with necrotizing vasculitis treated with immunosuppression. ( Jellinger, K; Kothbauer, P; Sunder-Plassmann, E; Weiss, R, 1979)
" Nonhematologic grade 3/4 adverse events were reported in 35% of once-weekly patients and 51% of twice-weekly patients (P = ."	2.75	Efficacy and safety of once-weekly bortezomib in multiple myeloma patients. ( Benevolo, G; Boccadoro, M; Bringhen, S; Callea, V; Cangialosi, C; Cavalli, M; Cavo, M; De Rosa, L; Evangelista, A; Falcone, AP; Gaidano, G; Gentili, S; Genuardi, M; Grasso, M; Guglielmelli, T; Larocca, A; Levi, A; Liberati, AM; Musto, P; Nozzoli, C; Palumbo, A; Patriarca, F; Ria, R; Rizzo, V; Rossi, D, 2010)
"Inflammatory peripheral neuropathies can be disabling for any patient."	2.72	Immunotherapy for Peripheral Nerve Disorders. ( Granger, A; Zakin, E, 2021)
"Waldenström's macroglobulinemia is a rare malignant disorder of B lymphocytes."	2.70	IFN-alpha as induction and maintenance treatment of patients newly diagnosed with Waldenström's macroglobulinemia. ( Abraham-Majluf, S; Arenas-Osuna, J; Aviña-Zubieta, JA; García-Chávez, J; García-Ruiz Esparza, MA; Padilla-González, Y; Rosas-Cabral, A; Salazar-Exaire, D; Vadillo-Buenfil, M; Vela-Ojeda, J; Xolotl-Castillo, M, 2002)
"When unrecognized and therefore untreated, vasculitis of the nervous system leads to pervasive injury and disability making this a disorder of paramount importance to all clinicians."	2.42	Vasculitis of the nervous system. ( Younger, DS, 2004)
"Only a few cases of hypersensitivity angiitis related to naproxen have been described."	2.41	Naproxen-induced leukocytoclastic vasculitis. ( Balbir-Gurman, A; Nahir, AM; Schapira, D, 2000)
"A man with multicentric angiofollicular lymph node hyperplasia and a polyclonal gammopathy developed a debilitating sensory-motor peripheral neuropathy that resolved with plasma-pheresis and immunosuppressive therapy."	2.38	Angiofollicular lymph node hyperplasia and peripheral neuropathy. Case report and literature review. ( May, E; Scherokman, B; Vukelja, SJ, 1991)
"A human mechanistic physiology-based pharmacokinetic (PBPK) model of vincristine following intravenous dosing was developed to predict potential DDI interactions with combination therapy."	1.62	Mechanistic physiology-based pharmacokinetic modeling to elucidate vincristine-induced peripheral neuropathy following treatment with novel kinase inhibitors. ( Chen, B; Fretland, AJ; McGinnity, DF; Pilla Reddy, V; Sharma, S; Vishwanathan, K; Ware, JA; Xu, Y; Zhou, D, 2021)
"Substantial efficacy has been demonstrated with bortezomib-melphalan-prednisone in phase III studies in transplant-ineligible myeloma patients using various twice-weekly and once-weekly bortezomib dosing schedules."	1.40	Bortezomib cumulative dose, efficacy, and tolerability with three different bortezomib-melphalan-prednisone regimens in previously untreated myeloma patients ineligible for high-dose therapy. ( Boccadoro, M; Bringhen, S; Desai, A; Di Raimondo, F; Esseltine, DL; García-Sanz, R; Lahuerta, JJ; Larocca, A; Londhe, A; Mateos, MV; Oriol, A; Palumbo, A; Richardson, PG; San Miguel, JF; van de Velde, H, 2014)
"After release from treatment, leprosy patients may insidiously develop progressive peripheral nerve symptoms not fulfilling criteria for relapse or leprosy reactions."	1.39	Late onset neuropathy in leprosy patients released from treatment: not all due to reactions? ( Cardoso, Fde M; De Freitas, MR; Escada, TM; Nascimento, OJ; Nevares, MT, 2013)
"In humans and dogs, paraneoplastic peripheral neuropathies have been documented with different neoplastic processes including lymphoproliferative disorders."	1.35	Peripheral neuropathy in a cat with renal lymphoma. ( Capucchio, MT; Catalano, D; Cavana, P; Farca, AM; Sammartano, F; Valazza, A, 2009)
"Neurosarcoidosis is a great mimicker."	1.32	Sarcoidosis of the cauda equina mimicking Guillain-Barré syndrome. ( Lewis, RA; Shah, JR, 2003)
"We describe a case of idiopathic hypereosinophilic syndrome manifested by an axonal sensory-motor polyneuropathy (ASMP) and signals of myositis."	1.32	[Peripheral neuropathy and myositis in idiopathic hypereosinophilic syndrome: case report]. ( Fabiani, G; Mücke, D; Scola, RH; Trentin, AP; Werneck, LC, 2004)
"From 536 patients with the CREST syndrome (calcinosis, Raynaud's phenomenon, esophageal dysmotility, sclerodactyly, and telangiectasis), seven were identified as having peripheral neuropathy not attributable to another cause."	1.30	A case-control and nerve biopsy study of CREST multiple mononeuropathy. ( Dyck, PJ; Hunder, GG, 1997)
"Electrophysiological studies revealed demyelination in all patients and axonal damage in 94."	1.30	[Chronic inflammatory demyelinating polyradiculoneuropathy. Study of 18 cases]. ( Calia, LC; Gabbai, AA; Oliveira, AS, 1997)
"Hypereosinophilia was probably idiopathic, however the presence of atypical findings suggested transition to vasculitides or collagen disease."	1.28	Peripheral neuropathy associated with hypereosinophilia. ( Dall'Asta, D; Fornaciari, G; Gemignani, F; Guidetti, D; Marbini, A; Ragni, P; Terenziani, S, 1991)
"Four cases of angioimmunoblastic lymphadenopathy associated to peripheral neuropathy are described."	1.26	[Neuropathy in angioimmunoblastic lymphadenopathy (author's transl)]. ( Binet, JL; Brunet, P; De Baecque, C; de Saxce, H; Gray, F; Lyon-Caen, O; Raphael, M, 1981)

Research

Studies (138)

Authors

Clinical Trials (8)

Trial Overview

Trial Outcomes

Change From Baseline to End of Treatment in the Global Health Status Score of the European Organization for Research and Treatment of Cancer (EORTC) 30-item Core Quality of Life Questionnaire (QLQ-C30)

Timeframe	Studies, this research(%)	All Research%
pre-1990	51 (36.96)	18.7374
1990's	38 (27.54)	18.2507
2000's	24 (17.39)	29.6817
2010's	17 (12.32)	24.3611
2020's	8 (5.80)	2.80

Authors	Studies
Hankard, A	1
Ingen-Housz-Oro, S	1
El Karoui, K	1
Paule, R	1
Lioger, B	1
Brihaye, B	1
Battistella, M	1
Jobard, S	1
Magnant, J	1
Diot, E	1
Bigot, A	1
Ferreira-Maldent, N	1
Deriaz, S	1
Cook, AR	1
Henique, H	1
Maillot, F	1
Aouba, A	1
Audemard-Verger, A	1
Fargetti, S	1
Ugolini-Lopes, MR	1
Pasoto, SG	1
Seguro, LPC	1
Shinjo, SK	1
Bonfa, E	1
Borba, EF	1
Rausch, CR	1
Jabbour, EJ	1
Kantarjian, HM	1
Kadia, TM	1
Bartlett, NL	1
Nakai, Y	1
Tanaka, N	1
Ichikawa, K	1
Miyake, M	1
Anai, S	1
Fujimoto, K	1
Hatzl, S	1
Posch, F	1
Rezai, A	1
Gornicec, M	1
Beham-Schmid, C	1
Magnes, T	1
Wangner, S	1
Deutsch, A	1
Greinix, H	1
Uhl, B	1
Prochazka, KT	1
Egle, A	1
Greil, R	1
Melchardt, T	1
Linkesch, W	1
Schulz, E	1
Neumeister, P	1
Granger, A	1
Zakin, E	1
Pilla Reddy, V	1
Fretland, AJ	1
Zhou, D	1
Sharma, S	1
Chen, B	1
Vishwanathan, K	1
McGinnity, DF	1
Xu, Y	1
Ware, JA	1
Lee, SE	2
Choi, K	1
Han, S	1
Lee, J	1
Hong, T	1
Park, GJ	1
Yim, DS	1
Min, CK	1
Lin, Z	1
Chen, X	1
Li, Z	1
Zhou, Y	1
Fang, Z	1
Luo, Y	1
Zhao, J	1
Xu, B	1
Saito, T	1
Okamura, A	1
Inoue, J	1
Makiura, D	1
Doi, H	1
Yakushijin, K	1
Matsuoka, H	1
Sakai, Y	1
Ono, R	1
Kobayashi, T	1
Kuroda, J	1
Fuchida, S	1
Murakami, S	1
Hatsuse, M	1
Okano, A	1
Iwai, T	1
Tsutsumi, Y	1
Kamitsuji, Y	1
Akaogi, T	1
Kawata-Iida, E	1
Shimizu, D	1
Uchiyama, H	1
Matsumoto, Y	2
Horiike, S	1
Nakao, M	1
Takahashi, R	1
Kaneko, H	1
Uoshima, N	1
Kobayashi, Y	1
Shimazaki, C	1
Taniwaki, M	1
Cardoso, Fde M	1
De Freitas, MR	1
Escada, TM	1
Nevares, MT	1
Nascimento, OJ	2
Palumbo, A	4
Bringhen, S	3
Larocca, A	3
Rossi, D	2
Di Raimondo, F	2
Magarotto, V	1
Patriarca, F	2
Levi, A	2
Benevolo, G	2
Vincelli, ID	1
Grasso, M	2
Franceschini, L	1
Gottardi, D	1
Zambello, R	1
Montefusco, V	1
Falcone, AP	2
Omedé, P	1
Marasca, R	1
Morabito, F	1
Mina, R	1
Guglielmelli, T	2
Nozzoli, C	2
Passera, R	1
Gaidano, G	2
Offidani, M	1
Ria, R	2
Petrucci, MT	1
Musto, P	2
Boccadoro, M	3
Cavo, M	2
Flinn, IW	1
van der Jagt, R	1
Kahl, BS	1
Wood, P	1
Hawkins, TE	1
Macdonald, D	1
Hertzberg, M	1
Kwan, YL	1
Simpson, D	1
Craig, M	1
Kolibaba, K	1
Issa, S	1
Clementi, R	1
Hallman, DM	1
Munteanu, M	1
Chen, L	1
Burke, JM	1
Mateos, MV	2
Richardson, PG	2
Lahuerta, JJ	1
Oriol, A	1
García-Sanz, R	1
Esseltine, DL	2
van de Velde, H	2
Desai, A	1
Londhe, A	1
San Miguel, JF	2
Berenguer-Potenciano, M	1
Villora-Morcillo, N	1
Nunez-Enamorado, N	1
Perez-Alonso, V	1
Camacho-Salas, A	1
Simon-De Las Heras, R	1
Ishida, T	1
Cohen, JB	1
Switchenko, JM	1
Koff, JL	1
Sinha, R	1
Kaufman, JL	1
Khoury, HJ	1
Bumpers, N	1
Colbert, A	1
Hutchison-Rzepka, A	1
Nastoupil, LJ	1
Heffner, LT	1
Langston, AA	1
Lechowicz, MJ	1
Lonial, S	1
Flowers, CR	1
Siniscalchi, A	1
Fratoni, S	1
Santeusanio, G	1
Del Poeta, G	1
de Fabritiis, P	1
Caravita, T	1
Cavana, P	1
Sammartano, F	1
Capucchio, MT	1
Catalano, D	1
Valazza, A	1
Farca, AM	1
Parasole, R	1
Petruzziello, F	1
Menna, G	1
Mangione, A	1
Cianciulli, E	1
Buffardi, S	1
Marchese, L	1
Nastro, A	1
Misuraca, A	1
Poggi, V	1
Cavalli, M	1
Genuardi, M	1
Gentili, S	1
Callea, V	1
Rizzo, V	1
Cangialosi, C	1
De Rosa, L	1
Liberati, AM	1
Evangelista, A	1
Dimopoulos, MA	2
Schlag, R	1
Khuageva, NK	1
Shpilberg, O	1
Kropff, M	1
Spicka, I	1
Wu, KL	1
Liu, K	1
Deraedt, W	1
Cakana, A	1
Felipez, LM	1
Gokhale, R	1
Tierney, MP	1
Kirschner, BS	1
Paik, JS	1
Cho, WK	1
Choi, BO	1
Jung, SE	1
Park, GS	1
Kim, SH	1
Yang, SW	1
Cho, SG	1
Nakashima, T	1
Kiba, T	1
Ogawa, Y	1
Kimura, A	1
Kido, M	1
Okikawa, Y	1
Ito, T	1
Saito, A	1
Hosokawa, A	1
Shintani, H	1
Okada, Y	1
Taniguchi, T	1
Taniyama, K	1
Kozawa, K	1
Niimi, H	1
Vela-Ojeda, J	1
García-Ruiz Esparza, MA	1
Padilla-González, Y	1
Rosas-Cabral, A	1
García-Chávez, J	1
Xolotl-Castillo, M	1
Salazar-Exaire, D	1
Arenas-Osuna, J	1
Aviña-Zubieta, JA	1
Vadillo-Buenfil, M	1
Abraham-Majluf, S	1
Gomes, C	1
L'heveder, G	1
Vandhuick, O	1
Mabin, D	1
Saraux, A	1
Shah, JR	1
Lewis, RA	1
Nodera, H	1
Barbano, RL	1
Henderson, D	1
Herrmann, DN	1
MORITZ, U	1
GARGOUR, G	1
MACGAFFEY, K	1
LOCKE, S	1
STEIN, MD	1
PALLIS, CA	1
SCOTT, JT	1
Vrancken, AF	1
Notermans, NC	2
Jansen, GH	1
Wokke, JH	1
Said, G	1
Scola, RH	1
Trentin, AP	1
Fabiani, G	1
Mücke, D	1
Werneck, LC	1
Younger, DS	1
Collins, MP	1
Periquet, MI	1
Ben Ghorbel, I	2
Ibnelhadj, Z	1
Zouari, M	1
Nagi, S	1
Khanfir, M	1
Hentati, F	1
Houman, MH	1
Noguchi, M	1
Yoshita, M	1
Sakai, K	1
Arahata, M	1
Ontachi, Y	1
Takami, A	1
Nakao, S	1
Sato, K	1
Yamada, M	1
Lin, PT	1
Andersson, PB	1
Distad, BJ	1
Barohn, RJ	1
Cho, SC	1
So, YT	1
Katz, JS	1
Dixit, A	1
Kannan, M	1
Mahapatra, M	1
Choudhry, VP	1
Saxena, R	1
Suzuki, C	1
Tomiyama, M	1
Baba, M	1
Jinichi, N	1
Ogawa, M	1
Kurahashi, K	1
Kamijo, M	1
Briani, C	1
Scarlato, M	1
Pavan, A	1
Marcolongo, R	1
Rondinone, R	1
Adami, F	1
Mantadakis, E	1
Amoiridis, G	1
Kondi, A	1
Kalmanti, M	1
Kawasaki, I	1
Shimada, Y	1
Mori, K	1
Yoneya, S	1
Kato, M	1
Anand, R	1
Arroyo, JG	1
Emerson, MV	1
Flaxel, CJ	1
Jardim, MR	1
Illarramendi, X	1
Nery, JA	1
Sales, AM	1
Sampaio, EP	1
Sarno, EN	1
Hatzitolios, A	1
Savopoulos, C	1
Ntaios, G	1
Tsirogianni, E	1
Baltatzi, M	1
Apostolopoulou, M	1
Dimitrakoudi, E	1
Ramos, A	1
Roustán, G	1
Angel-Moreno, A	1
Suárez, E	1
Bakemeier, RF	1
Anderson, JR	1
Costello, W	1
Rosner, G	1
Horton, J	1
Glick, JH	1
Hines, JD	1
Berard, CW	1
DeVita, VT	1
Dalakas, MC	2
Engel, WK	3
Waldo, RT	1
Geltner, D	1
Kohn, RW	1
Gorevic, P	1
Franklin, EC	1
Brunet, P	1
Binet, JL	1
de Saxce, H	1
Gray, F	1
De Baecque, C	1
Raphael, M	1
Lyon-Caen, O	1
Hineman, VL	1
Phyliky, RL	1
Banks, PM	1
Dux, S	1
Pitlik, S	1
Rosenfeld, JB	1
Kelly, JJ	2
Kyle, RA	1
Miles, JM	1
Dyck, PJ	3
Massey, EW	1
Sumi, SM	1
Farrell, DF	1
Knauss, TA	1
Flaum, MA	1
Rick, M	1
Gralnick, HR	1
Steere, AC	1
Pachner, AR	1
Malawista, SE	1
Touw-Langendijk, EM	1
Brandsma, JW	1
Andersen, JG	1
Donofrio, PD	1
Albers, JW	2
Greenberg, HS	1
Mitchell, BS	1
Streib, EW	1
Sun, SF	1
Bradley, WG	2
Chad, D	1
Verghese, JP	1
Liu, HC	1
Good, P	1
Gabbai, AA	2
Adelman, LS	1
Frazier, TC	1
Stafford, CT	1
Pinar, G	1
Figols, J	1
Berciano, J	1
Pascual, J	1
Moreaud, O	1
Mezin, P	1
De Saint Victor, JF	1
Noelle, B	1
Berger, F	1
Pellat, J	1
Shulman, LN	1
Buswell, L	1
Kalish, LA	1
Coleman, CN	1
Boulloche, J	1
Slim, S	1
Le Luyer, B	1
Mallet, E	1
Tron, P	1
Le Roux, P	1
Lienhardt, PY	1
Coudray, C	1
Chamouard, JM	1
Smadja, D	1
Chaunu, MP	1
Bouche, P	1
Ike, RW	1
Blaivas, M	1
Postma, TJ	1
Benard, BA	1
Huijgens, PC	1
Ossenkoppele, GJ	1
Heimans, JJ	1
Pareyson, D	1
Ciano, C	1
Fiacchino, F	1
Gemma, M	1
Savoiardo, M	1
Sghirlanzoni, A	1
Lazzarino, LG	1
Nicolai, A	1
Cavallaro, T	1
Rizzuto, N	1
Mateos-Colino, A	1
Gonzalez-Gay, MA	1
Cereijo, MJ	1
Santiago, J	1
Rabuñal, R	1
Brañas, F	1
Sladky, JT	3
Comenzo, RL	1
Vosburgh, E	1
Simms, RW	1
Bergethon, P	1
Sarnacki, D	1
Finn, K	1
Dubrey, S	1
Faller, DV	1
Wright, DG	1
Falk, RH	1
Skinner, M	1
Tomasina, C	1
Manzino, M	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
A PHASE III, MULTI-CENTER, RANDOMIZED OPEN LABEL STUDY OF VELCADE, MELPHALAN, PREDNISONE AND THALIDOMIDE (V-MPT) Versus VELCADE, MELPHALAN, PREDNISONE (V-MP) IN ELDERLY UNTREATED MULTIPLE MYELOMA PATIENTS[NCT01063179]	Phase 3	511 participants (Actual)	Interventional	2006-05-31	Completed
A Prospective, Observational Study, to Evaluate the Maintenance With Bortezomib Plus Daratumumab (V-Dara) After Induction With Bortezomib, Melphalan, Prednisone Plus Daratumumab (VMP-Dara) in Newly Diagnosed Multiple Myeloma (MM) Patients Non-eligible for[NCT05218603]		100 participants (Anticipated)	Observational	2021-11-30	Recruiting
An Open-Label, Randomized, Parallel-Group Study of Bendamustine Hydrochloride and Rituximab (BR) Compared With Rituximab, Cyclophosphamide, Vincristine, and Prednisone (R-CVP) or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHO[NCT00877006]	Phase 3	447 participants (Actual)	Interventional	2009-04-30	Completed
Isatuximab and Bendamustine in Systemic Light Chain Amyloidosis[NCT04943302]	Phase 2	0 participants (Actual)	Interventional	2022-09-30	Withdrawn (stopped due to PI left institution. Study not moving forward in her absence.)
A Randomized Phase II Trial Comparing BeEAM With BEAM as Conditioning Regimen for Autologous Stem Cell Transplantation (ASCT) in Lymphoma Patients (BEB-trial)[NCT02278796]	Phase 2	108 participants (Actual)	Interventional	2015-04-30	Completed
A Phase I/II Trial of VR-CHOP for Patients With Untreated Follicular Lymphoma and Other Low Grade B-Cell Lymphomas[NCT00634179]	Phase 1/Phase 2	37 participants (Actual)	Interventional	2008-02-29	Completed
A Pilot Study on the Efficacy of Daratumumab in Multiple Myeloma (MM) Patients in >VGPR/MRD-positive by Next Generation Flow[NCT03992170]	Phase 2	50 participants (Anticipated)	Interventional	2018-12-31	Recruiting
An Open-Label, Randomized Study of VELCADE/Melphalan/Prednisone Versus Melphalan/Prednisone in Subjects With Previously Untreated Multiple Myeloma[NCT00111319]	Phase 3	0 participants	Interventional	2004-12-31	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

EORTC QLQ-C30 is a 30-item questionnaire to assess the overall quality of life in cancer patients. EORTC QLQ-C30 includes functional scales (physical, role, cognitive, emotional, and social), global health status, symptom scales (fatigue, pain, nausea/vomiting), and other (dyspnoea, appetite loss, insomnia, constipation/diarrhea, and financial difficulties). This outcome reports the global health status on a scale of 0-100 with a high score for the global health status/QOL represents a high quality of life. (NCT00877006)
Timeframe: Day 1 (prior to treatment), 32 weeks

Kaplan-Meier Estimate for Duration of Response (DOR)

Intervention	units on a scale (Mean)
Bendamustine and Rituximab (BR)	3.6
R-CHOP/R-CVP	-5.1

DOR was defined as the time from first response (CR or PR) to disease progression or relapse, or death due to any cause. (NCT00877006)
Timeframe: Day 1 up to 5.6 years (Treatment Period + Long-Term Follow-up Period)

Kaplan-Meier Estimate for Event-free Survival (EFS)

Intervention	months (Median)
Bendamustine and Rituximab (BR)	26.5
R-CHOP/R-CVP	32.1

"EFS was defined as the time from randomization to treatment failure, disease progression or relapse, other malignancies, or death from any cause, whichever occurred first.~Treatment failure was defined as failure to achieve a CR or PR after 6 cycles of treatment. If a patient failed to achieve CR or PR by the time of data analysis or early withdrawal, the treatment failure date was set at 126 days (6 cycles of treatment) after randomization or the new anticancer treatment date, whichever is earlier." (NCT00877006)
Timeframe: Day 1 up to 5.6 years (Treatment Period + Long-Term Follow-up Period)

Kaplan-Meier Estimate for Progression-free Survival (PFS)

Intervention	months (Median)
Bendamustine and Rituximab (BR)	31.8
R-CHOP/R-CVP	32.6

PFS was defined as the time from randomization to disease progression or relapse, or death from any cause, whichever occurred first. (NCT00877006)
Timeframe: Day 1 up to 5.6 years (Treatment Period + Long-Term Follow-up Period)

Overall Survival (OS)

Intervention	months (Median)
Bendamustine and Rituximab (BR)	31.8
R-CHOP/R-CVP	33.4

OS was defined as the time from randomization to death from any cause. (NCT00877006)
Timeframe: Day 1 up to 5.6 years (Treatment Period + Long-Term Follow-up Period)

Participants With Disease Progression, Relapse or Death At the End of the Treatment Period or the Long-Term Follow-up Period

Intervention	months (Median)
Bendamustine and Rituximab (BR)	65.0
R-CHOP/R-CVP	64.1

"Relapsed disease (after CR) and progressive disease (PD) (after PR or SD):~Lymph nodes were considered abnormal if the long axis was greater than 1.5 cm. Lymph nodes with a long axis of 1.1 to 1.5 cm were considered abnormal if its short axis was greater than 1.0 cm.~In patients with no prior history of pulmonary lymphoma, new lung nodules identified by CT require histologic confirmation.~>= 50% increase from nadir in sum of the products of the greatest diameters (SPD) of any previously involved nodes, or in a single involved node, or the size of other lesions (eg, splenic or hepatic nodules). To be considered progressive disease, a lymph node with a diameter of the short axis of less than 1.0 cm must have increased by 2: 50% and to a size of 1.5 cm by 1.5 cm, or more than 1.5 cm in the long axis~other conditions as specified in the protocol" (NCT00877006)
Timeframe: Treatment Period: 18-32 weeks Long-Term Follow-up Period: up to 5 years after the Treatment Period

Percentage of Participants With Complete Response (CR) at End of Treatment Period

Intervention	Participants (Count of Participants)
Bendamustine and Rituximab (BR)	36
R-CHOP/R-CVP	30

CR=complete disappearance of all detectable clinical evidence of disease and disease-related symptoms, if present pretherapy; protocol-specified positron emission tomography (PET) scan assessment criteria; (if the spleen and/or liver were enlarged on the basis of physical examination and/or anatomic imaging before treatment) the liver and/or spleen were considered normal size on physical examination and by anatomic imaging after therapy, with disappearance of all nodules related to lymphoma; (if the bone marrow was involved by lymphoma before treatment) the infiltrate must have cleared on subsequent bone marrow biopsies. (NCT00877006)
Timeframe: 6 to 8 21 or 28-day cycles (18-32 weeks)

Percentage of Participants With Overall Response at End of Treatment Period

Intervention	percentage of participants (Number)
Bendamustine and Rituximab (BR)	31
R-CHOP/R-CVP	25

Overall Response=participants with Complete Remission (CR) + those with Partial Remission (PR). CR=see Outcome Measure 1 for details. PR= at least a 50% decrease in the sum of the product of the greatest diameters (SPD) of up to 6 of the largest dominant nodes/masses; at least a 50% decrease in the SPD of hepatic and splenic nodules in their greatest transverse diameter; no increase in the size of the liver, spleen, and other nodes; no measurable disease in organs other than the liver or spleen; no new sites of disease; protocol-specified PET scan and bone marrow criteria. (NCT00877006)
Timeframe: 6 to 8 21 or 28-day cycles (18-32 weeks)

Clinically Significant Abnormal Vital Signs

Intervention	percentage of participants (Number)
Bendamustine and Rituximab (BR)	97
R-CHOP/R-CVP	91

(NCT00877006)
Timeframe: 32 weeks (conducted at screening, Day 1 of each cycle, and end-of-treatment visit)

Eastern Cooperative Oncology Group (ECOG) Performance Status at the End of Treatment Period

Intervention	participants (Number)
	Heart Rate >=120 and ↑ >=15 bpm	Heart Rate <=50 and ↓ >=15 bpm	Systolic Blood Pressure(BP) >=180 and ↑ >=20 mm Hg	Systolic BP <=90 and ↓ >=20 mm Hg	Diastolic BP >=105 and ↑ from Baseline >=15 mm Hg	Diastolic BP <=50 and ↓ from Baseline >=15 mm Hg
Bendamustine and Rituximab (BR)	0	2	2	6	1	2
R-CHOP/R-CVP	1	2	2	2	2	2

Participants' ECOG Performance Status was evaluated at the end of treatment as improved, stayed the same, or worsened from baseline (see Baseline Characteristics for ECOG Performance Status). (NCT00877006)
Timeframe: Week 32

Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), Deaths and Discontinuations Due to AEs at End of Treatment Period

Intervention	participants (Number)
	Improved	Stayed the Same	Worsened
Bendamustine/Rituximab	32	153	34
R-CHOP/R-CVP	28	141	42

AE=any untoward medical occurrence that develops or worsens in severity after dispensation of the study drug and does not necessarily have a causal relationship to the study drug. An AE can, therefore, be any unfavorable and unintended physical sign, symptom, or laboratory parameter that develops or worsens in severity during the course of the study, or significant worsening of the disease under study (or any concurrent disease), whether or not considered related to the study drug. AEs were graded as 1 (mild), 2 (moderate), 3 (severe), 4 (life-threatening), 5 (death). SAE=an adverse event occurring at any dose that results in: death, a life-threatening adverse event, inpatient hospitalization or prolongation of existing hospitalization, a persistent or significant disability/incapacity (a substantial disruption of one's ability to conduct normal life functions), a congenital anomaly/birth defect, or other important medical event. (NCT00877006)
Timeframe: 32 weeks

Participants Who Died At the End of the Treatment Period or the Long-Term Follow-up Period

Intervention	participants (Number)
	Any AE	Severe AEs (grades 3, 4, 5)	Treatment-related AEs	Deaths	SAEs	Withdrawn due to AEs
Bendamustine and Rituximab (BR)	221	130	209	12	60	10
R-CHOP/R-CVP	213	127	NA	9	49	3

Death is due to any cause. Data are broken out by patients who died within 30 days of the last dose of study medications, and those who died greater than 30 days of the last dose of study medications. (NCT00877006)
Timeframe: Treatment Period: 18-32 weeks Long-Term Follow-up Period: up to 5 years after the Treatment Period

Potentially Clinically Significant Abnormal Weight

Intervention	Participants (Count of Participants)
	All Deaths	Deaths within 30 days of study treatment	Deaths greater than 30 days of study treatment
Bendamustine and Rituximab (BR)	40	2	38
R-CHOP/R-CVP	32	1	31

Participants were weighed at Baseline and at Endpoint (Week 32); those participants with an increase or decrease of >=10% were considered potentially clinically significant. (NCT00877006)
Timeframe: Baseline, Week 32

Therapeutic Classification of Concomitant Medications

Therapeutic Classification of Prior Medications

Worst Overall Common Terminology Criteria for Adverse Events (CTCAE) Grades for Serum Chemistry Laboratory Test Results

Intervention	participants (Number)
	Increase >=10%	Decrease >=10%
Bendamustine and Rituximab (BR)	8	18
R-CHOP/R-CVP	5	8

Intervention	participants (Number)
	Psycholeptics	Sex Hormones and Modulators of the Genital System	Stomatological Preparations	Throat Preparations	Thyroid Therapy	Topical Preparations for Join and Muscular Pain	Unspecified Herbal	Urologicals	Vaccines	Vasoprotectives	Vitamins
Bendamustine and Rituximab (BR)	69	6	23	3	3	1	3	5	11	1	16
R-CHOP/R-CVP	74	4	29	2	1	2	5	4	11	8	21

Intervention	participants (Number)
	Psycholeptics	Sex Hormones and Modulators of the Genital System	Stomatological Preparations	Throat Preparations	Thyroid Therapy	Topical Products for Join and Muscular Pain	Unspecified Herbal	Urologicals	Vaccines	Vasoprotectives	Vitamins
Bendamustine and Rituximab (BR)	57	11	0	0	16	1	10	20	2	0	70
R-CHOP/R-CVP	59	12	0	0	17	0	10	11	7	0	61

Clinical laboratory data were graded according to National Cancer Institute's (NCI) CTCAE version 3, and graded as 1 (mild), 2 (moderate), 3 (severe), 4 (life-threatening), 5 (death). The table presents the worst CTCAE grades for serum chemistry test results experienced by participants overall (i.e., the worst post-baseline grade value for each participant and laboratory test across all cycles). (NCT00877006)
Timeframe: 32 weeks (conducted at screening, Day 1 of each cycle, and end-of-treatment visit)

Worst Overall CTCAE Grade for Hematology Laboratory Test Results

Intervention	participants (Number)
	Albumin: Grade 1	Albumin: Grade 2	Albumin: Grade 3	Albumin: Grade 4	Albumin: Grades 1-4	Alkaline Phosphatase: Grade 1	Alkaline Phosphatase: Grade 2	Alkaline Phosphatase: Grade 3	Alkaline Phosphatase: Grade 4	Alkaline Phosphatase: Grades 1-4	Creatinine: Grade 1	Creatinine: Grade 2	Creatinine: Grade 3	Creatinine: Grade 4	Creatinine: Grades 1-4	Gamma-glutamyl transferase: Grade 1	Gamma-glutamyl transferase: Grade 2	Gamma-glutamyl transferase: Grade 3	Gamma-glutamyl transferase: Grade 4	Gamma-glutamyl transferase: Grades 1-4	Hypercalcemia: Grade 1	Hypercalcemia: Grade 2	Hypercalcemia: Grade 3	Hypercalcemia: Grade 4	Hypercalcemia: Grades 1-4	Hyperglycemia: Grade 1	Hyperglycemia: Grade 2	Hyperglycemia: Grade 3	Hyperglycemia: Grade 4	Hyperglycemia: Grades 1-4	Hyperkalemia: Grade 1	Hyperkalemia: Grade 2	Hyperkalemia: Grade 3	Hyperkalemia: Grade 4	Hyperkalemia: Grades 1-4	Hypernatremia: Grade 1	Hypernatremia: Grade 2	Hypernatremia: Grade 3	Hypernatremia: Grade 4	Hypernatremia: Grades 1-4	Hypocalcemia: Grade 1	Hypocalcemia: Grade 2	Hypocalcemia: Grade 3	Hypocalcemia: Grade 4	Hypocalcemia: Grades 1-4	Hypoglycemia: Grade 1	Hypoglycemia: Grade 2	Hypoglycemia: Grade 3	Hypoglycemia: Grade 4	Hypoglycemia: Grades 1-4	Hypokalemia: Grade 1	Hypokalemia: Grade 2	Hypokalemia: Grade 3	Hypokalemia: Grade 4	Hypokalemia: Grades 1-4	Hyponatremia: Grade 1	Hyponatremia: Grade 2	Hyponatremia: Grade 3	Hyponatremia: Grade 4	Hyponatremia: Grades 1-4	Magnesium: Grade 1	Magnesium: Grade 2	Magnesium: Grade 3
Bendamustine and Rituximab (BR)	33	14	3	0	50	41	1	0	0	42	19	3	1	0	23	31	18	3	0	52	6	0	1	0	7	94	20	15	0	129	7	3	1	0	11	8	0	0	0	8	36	8	1	3	48	15	1	0	0	16	18	0	0	0	18	40	0	0	0	40	46	0	0
R-CHOP/R-CVP	44	13	0	0	57	25	3	0	0	28	25	1	0	0	26	37	10	6	0	53	6	0	0	0	6	74	34	15	1	124	8	1	0	0	9	10	0	0	0	10	28	6	0	0	34	10	0	0	0	10	16	0	1	0	17	28	0	5	0	33	44	1	1

Hematology test data were graded according to National Cancer Institute's (NCI) CTCAE version 3, and graded as 1 (mild), 2 (moderate), 3 (severe), 4 (life-threatening), 5 (death). The table presents the worst CTCAE grades for hematology test results experienced by participants overall (i.e., the worst post-baseline grade value for each participant and hematology test across all cycles). (NCT00877006)
Timeframe: 32 weeks (conducted at screening, Day 1 of each cycle, weekly during treatment, and at the end-of-treatment visit)

Maximal Tolerated Doses of Bortezomib and Vincristine When Used in Combination of Bortezomib, Rituximab and the CHOP Chemotherapy Regimen (Phase I)

Intervention	participants (Number)
	Absolute Neutrophil Count: Grade 1	Absolute Neutrophil Count: Grade 2	Absolute Neutrophil Count: Grade 3	Absolute Neutrophil Count: Grade 4	Absolute Neutrophil Count: Grades 1-4	Hemoglobin: Grade 1	Hemoglobin: Grade 2	Hemoglobin: Grade 3	Hemoglobin: Grade 4	Hemoglobin: Grades 1-4	Lymphocytes Absolute: Grade 1	Lymphocytes Absolute: Grade 2	Lymphocytes Absolute: Grade 3	Lymphocytes Absolute: Grade 4	Lymphocytes Absolute: Grades 1-4	Platelets: Grade 1	Platelets: Grade 2	Platelets: Grade 3	Platelets: Grade 4	Platelets: Grades 1-4	White Blood Cells: Grade 1	White Blood Cells: Grade 2	White Blood Cells: Grade 3	White Blood Cells: Grade 4	White Blood Cells: Grades 1-4
Bendamustine and Rituximab (BR)	22	51	48	50	171	129	42	5	1	177	1	5	54	83	143	106	14	9	7	136	41	79	65	19	204
R-CHOP/R-CVP	14	20	47	104	185	129	51	7	2	189	6	55	55	9	125	72	14	7	8	101	22	49	89	27	187

INDUCTION: Patients receive bortezomib IV on days 1 and 8; rituximab IV, doxorubicin hydrochloride IV over 3-5 minutes, cyclophosphamide IV over 60 minutes, and vincristine sulfate IV over 10 minutes on day 1; and prednisone PO on days 1-5. Treatment repeats every 21 days for up to 8 courses in the absence of disease progression. (NCT00634179)
Timeframe: Cycle 1 for MTD, following completion of therapy for CR, up to 24 weeks

An Estimate of the Overall Response Rate (ORR)(Complete Response [CR] + CR Unconfirmed [CRu] + Partial Response [PR]) to Bortezomib and Rituximab (VR)-CHOP According to International Workshop to Standardize Response Criteria (IWRC) Criteria

Intervention	mg/m^2 (Number)
MTD of Bortezomib With Vincristine Capped at 1.5 mg	1.62

Response was assessed by computerized tomography (CT) after every 2 cycles of induction therapy, one time at least 4 weeks after completing induction (i.e., prior to maintenance), and then every 3 months while on maintenance therapy. At the conclusion of maintenance therapy, patients underwent one post-treatment scan, with further scans completed at the discretion of the treating physician. Positron emission tomography was permitted but only CT measurements were used to determine response. (NCT00634179)
Timeframe: Following completion of therapy, up to 2 years

Article	Year
Immunotherapy for Peripheral Nerve Disorders. Clinics in geriatric medicine, 2021, Volume: 37, Issue:2 Topics: Adrenal Cortex Hormones; Aged; Humans; Immunoglobulins, Intravenous; Immunologic Factors; Immunother	2021
The role of bortezomib in newly diagnosed diffuse large B cell lymphoma: a meta-analysis. Annals of hematology, 2018, Volume: 97, Issue:11 Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bortezomib;	2018
Progressive idiopathic axonal neuropathy--a comparative clinical and histopathological study with vasculitic neuropathy. Journal of neurology, 2004, Volume: 251, Issue:3 Topics: Adolescent; Adult; Aged; Analysis of Variance; Disease Progression; Female; Humans; Male; Middle Age	2004
Vasculitis of the nervous system. Current opinion in neurology, 2004, Volume: 17, Issue:3 Topics: Azathioprine; Connective Tissue Diseases; Cyclophosphamide; Diagnosis, Differential; Giant Cell Arte	2004
Non-systemic vasculitic neuropathy. Current opinion in neurology, 2004, Volume: 17, Issue:5 Topics: Anti-Inflammatory Agents; Cohort Studies; Diagnosis, Differential; Humans; Motor Neurons; Peripheral	2004
Immune neuropathies in childhood. Bailliere's clinical neurology, 1996, Volume: 5, Issue:1 Topics: Adolescent; Anti-Inflammatory Agents; Child; Child, Preschool; Humans; Infant; Male; Peripheral Nerv	1996
Bangkok Workshop on Leprosy Research. Treatment of reactions and nerve damage. International journal of leprosy and other mycobacterial diseases : official organ of the International Leprosy Association, 1996, Volume: 64, Issue:4 Suppl Topics: Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Clofazimine; Cyclosporine; Drug A	1996
Naproxen-induced leukocytoclastic vasculitis. Clinical rheumatology, 2000, Volume: 19, Issue:3 Topics: Anti-Inflammatory Agents, Non-Steroidal; Female; Glucocorticoids; Humans; Middle Aged; Naproxen; Nep	2000
Neuropathies and myopathies complicating HIV infection. Journal of clinical apheresis, 1991, Volume: 6, Issue:2 Topics: Acquired Immunodeficiency Syndrome; Action Potentials; Adult; Antiviral Agents; Azathioprine; Combin	1991
Angiofollicular lymph node hyperplasia and peripheral neuropathy. Case report and literature review. Archives of internal medicine, 1991, Volume: 151, Issue:4 Topics: Aged; Azathioprine; Castleman Disease; Humans; Immunosuppression Therapy; Male; Peripheral Nervous S	1991

Article	Year
Bortezomib pharmacokinetics in tumor response and peripheral neuropathy in multiple myeloma patients receiving bortezomib-containing therapy. Anti-cancer drugs, 2017, Volume: 28, Issue:6 Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone;	2017
Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: updated follow-up and improved survival. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2014, Mar-01, Volume: 32, Issue:7 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease-Free	2014
Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: updated follow-up and improved survival. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2014, Mar-01, Volume: 32, Issue:7 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease-Free	2014
Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: updated follow-up and improved survival. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2014, Mar-01, Volume: 32, Issue:7 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease-Free	2014
Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: updated follow-up and improved survival. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2014, Mar-01, Volume: 32, Issue:7 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease-Free	2014
Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study. Blood, 2014, May-08, Volume: 123, Issue:19 Topics: Adult; Aged; Aged, 80 and over; Alopecia; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Com	2014
Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study. Blood, 2014, May-08, Volume: 123, Issue:19 Topics: Adult; Aged; Aged, 80 and over; Alopecia; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Com	2014
Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study. Blood, 2014, May-08, Volume: 123, Issue:19 Topics: Adult; Aged; Aged, 80 and over; Alopecia; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Com	2014
Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study. Blood, 2014, May-08, Volume: 123, Issue:19 Topics: Adult; Aged; Aged, 80 and over; Alopecia; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Com	2014
Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study. Blood, 2014, May-08, Volume: 123, Issue:19 Topics: Adult; Aged; Aged, 80 and over; Alopecia; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Com	2014
Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study. Blood, 2014, May-08, Volume: 123, Issue:19 Topics: Adult; Aged; Aged, 80 and over; Alopecia; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Com	2014
Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study. Blood, 2014, May-08, Volume: 123, Issue:19 Topics: Adult; Aged; Aged, 80 and over; Alopecia; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Com	2014
Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study. Blood, 2014, May-08, Volume: 123, Issue:19 Topics: Adult; Aged; Aged, 80 and over; Alopecia; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Com	2014
Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study. Blood, 2014, May-08, Volume: 123, Issue:19 Topics: Adult; Aged; Aged, 80 and over; Alopecia; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Com	2014
A phase II study of bortezomib added to rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone in patients with previously untreated indolent non-Hodgkin's lymphoma. British journal of haematology, 2015, Volume: 171, Issue:4 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cyclophosphamide; Disease-F	2015
Efficacy and safety of once-weekly bortezomib in multiple myeloma patients. Blood, 2010, Dec-02, Volume: 116, Issue:23 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease-Free Surviv	2010
Efficacy and safety of once-weekly bortezomib in multiple myeloma patients. Blood, 2010, Dec-02, Volume: 116, Issue:23 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease-Free Surviv	2010
Efficacy and safety of once-weekly bortezomib in multiple myeloma patients. Blood, 2010, Dec-02, Volume: 116, Issue:23 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease-Free Surviv	2010
Efficacy and safety of once-weekly bortezomib in multiple myeloma patients. Blood, 2010, Dec-02, Volume: 116, Issue:23 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease-Free Surviv	2010
Risk factors for, and reversibility of, peripheral neuropathy associated with bortezomib-melphalan-prednisone in newly diagnosed patients with multiple myeloma: subanalysis of the phase 3 VISTA study. European journal of haematology, 2011, Volume: 86, Issue:1 Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib;	2011
IFN-alpha as induction and maintenance treatment of patients newly diagnosed with Waldenström's macroglobulinemia. Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research, 2002, Volume: 22, Issue:10 Topics: Aged; Chlorambucil; Disease-Free Survival; Drug Administration Schedule; Drug Therapy, Combination;	2002
BCVPP chemotherapy for advanced Hodgkin's disease: evidence for greater duration of complete remission, greater survival, and less toxicity than with a MOPP regimen. Results of the Eastern Cooperative Oncology Group study. Annals of internal medicine, 1984, Volume: 101, Issue:4 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; Carmustine; Clinical Trials	1984
Use of the hypoxic cell sensitizer etanidazole (SR-2508) with intravenous melphalan and prednisone in the treatment of multiple myeloma: a pharmacokinetic study. International journal of radiation oncology, biology, physics, 1994, Jun-15, Volume: 29, Issue:3 Topics: Antineoplastic Combined Chemotherapy Protocols; Etanidazole; Humans; Infusions, Intravenous; Melphal	1994
Dose-intensive melphalan with blood stem cell support for the treatment of AL amyloidosis: one-year follow-up in five patients. Blood, 1996, Oct-01, Volume: 88, Issue:7 Topics: Adult; Amyloidosis; Cardiomyopathies; Feasibility Studies; Female; Follow-Up Studies; Gastrointestin	1996
Clinical findings and prognosis of polyarteritis nodosa and Churg-Strauss angiitis: a study in 165 patients. British journal of rheumatology, 1988, Volume: 27, Issue:4 Topics: Adult; Age Factors; Aged; Cyclophosphamide; Female; Humans; Kidney Diseases; Male; Middle Aged; Peri	1988
Prednisone treatment for idiopathic facial paralysis (Bell's palsy). The New England journal of medicine, 1972, Dec-21, Volume: 287, Issue:25 Topics: Administration, Oral; Adult; Clinical Trials as Topic; Edema; Facial Muscles; Facial Nerve; Facial P	1972

Article	Year
IgA vasculitis with underlying monoclonal IgA gammopathy: innovative therapeutic approach targeting plasma cells. A case series. Clinical rheumatology, 2022, Volume: 41, Issue:10 Topics: Bortezomib; Cyclophosphamide; Dexamethasone; Humans; IgA Vasculitis; Immunoglobulin A; Lenalidomide;	2022
Short- and Long-Term Outcome of Systemic Lupus Erythematosus Peripheral Neuropathy: Bimodal Pattern of Onset and Treatment Response. Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases, 2021, Sep-01, Volume: 27, Issue:6S Topics: Humans; Immunosuppressive Agents; Lupus Erythematosus, Systemic; Peripheral Nervous System Diseases;	2021
Optimizing the use of the hyperCVAD regimen: Clinical vignettes and practical management. Cancer, 2020, 03-15, Volume: 126, Issue:6 Topics: Age Factors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Brai	2020
The justification of vincristine dose capping: tradition, tradition…tradition! Leukemia & lymphoma, 2020, Volume: 61, Issue:5 Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Etoposide; Humans; In	2020
Appropriate Number of Docetaxel Cycles in Castration-Resistant Prostate Cancer Patients Considering Peripheral Neuropathy and Oncological Control. Chemotherapy, 2020, Volume: 65, Issue:5-6 Topics: Aged; Aged, 80 and over; Dexamethasone; Docetaxel; Drug Administration Schedule; Humans; Male; Middl	2020
Vinorelbine as substitute for vincristine in patients with diffuse large B cell lymphoma and vincristine-induced neuropathy. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2021, Volume: 29, Issue:9 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Female; Hematop	2021
Mechanistic physiology-based pharmacokinetic modeling to elucidate vincristine-induced peripheral neuropathy following treatment with novel kinase inhibitors. Cancer chemotherapy and pharmacology, 2021, Volume: 88, Issue:3 Topics: Administration, Intravenous; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Pr	2021
Anemia Is a Novel Predictive Factor for the Onset of Severe Chemotherapy-Induced Peripheral Neuropathy in Lymphoma Patients Receiving Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisolone Therapy. Oncology research, 2019, Mar-29, Volume: 27, Issue:4 Topics: Adult; Aged; Anemia; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Pr	2019
The response to second-line induction with bortezomib and dexamethasone is predictive of long-term outcomes prior to high-dose chemotherapy with autologous stem cell transplantation for multiple myeloma. Internal medicine (Tokyo, Japan), 2013, Volume: 52, Issue:9 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chromosome A	2013
Late onset neuropathy in leprosy patients released from treatment: not all due to reactions? Leprosy review, 2013, Volume: 84, Issue:2 Topics: Adult; Anti-Inflammatory Agents; Female; Histocytochemistry; Humans; Leprostatic Agents; Leprosy; Ma	2013
Bortezomib cumulative dose, efficacy, and tolerability with three different bortezomib-melphalan-prednisone regimens in previously untreated myeloma patients ineligible for high-dose therapy. Haematologica, 2014, Volume: 99, Issue:6 Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease Progression; Huma	2014
[Therapeutic response to pyridoxine and pyridostigmine in a paediatric case of severe peripheral and cranial polyneuropathy due to vincristine]. Revista de neurologia, 2015, Jan-16, Volume: 60, Issue:2 Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Blepharoptosis; Cranial Nerve Diseases	2015
[Complications and managements in treatment of melphalan, prednisone and new agents]. Nihon rinsho. Japanese journal of clinical medicine, 2015, Volume: 73 Suppl 2 Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Humans; Melphalan; Molecu	2015
Cutaneous involvement in multiple myeloma and bortezomib. Annals of hematology, 2009, Volume: 88, Issue:11 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Fema	2009
Peripheral neuropathy in a cat with renal lymphoma. Journal of feline medicine and surgery, 2009, Volume: 11, Issue:10 Topics: Animals; Antineoplastic Agents, Hormonal; Cat Diseases; Cats; Euthanasia, Animal; Kidney Neoplasms;	2009
Central nervous system complications during treatment of acute lymphoblastic leukemia in a single pediatric institution. Leukemia & lymphoma, 2010, Volume: 51, Issue:6 Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Central Nervous System; Ce	2010
Thalidomide use and outcomes in pediatric patients with Crohn disease refractory to infliximab and adalimumab. Journal of pediatric gastroenterology and nutrition, 2012, Volume: 54, Issue:1 Topics: Adalimumab; Adolescent; Anti-Inflammatory Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Hu	2012
Ophthalmologic outcomes after chemotherapy and/or radiotherapy in non-conjunctival ocular adnexal MALT lymphoma. Annals of hematology, 2012, Volume: 91, Issue:9 Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherap	2012
[A case of neurotoxicity reduced with pregabalin in R-CHOP chemotherapy for diffuse large B-cell lymphoma]. Gan to kagaku ryoho. Cancer & chemotherapy, 2012, Volume: 39, Issue:5 Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophospha	2012
A case of cutaneous sensory neuropathy associated with Churg-Strauss syndrome. Joint bone spine, 2003, Volume: 70, Issue:1 Topics: Adult; Anti-Inflammatory Agents; Arthritis; Churg-Strauss Syndrome; Eosinophilia; Female; Fever; Hum	2003
Sarcoidosis of the cauda equina mimicking Guillain-Barré syndrome. Journal of the neurological sciences, 2003, Apr-15, Volume: 208, Issue:1-2 Topics: Adult; Anti-Inflammatory Agents; Cauda Equina; Diagnosis, Differential; Follow-Up Studies; Granuloma	2003
Epidermal reinnervation concomitant with symptomatic improvement in a sensory neuropathy. Muscle & nerve, 2003, Volume: 27, Issue:4 Topics: Anti-Inflammatory Agents; Biopsy; Epidermis; Humans; Male; Middle Aged; Nerve Regeneration; Peripher	2003
STUDIES ON MOTOR NERVE CONDUCTION IN RHEUMATOID ARTHRITIS. Acta rheumatologica Scandinavica, 1964, Volume: 10 Topics: Arthritis; Arthritis, Rheumatoid; Electric Stimulation; Electromyography; Electrophysiology; Humans;	1964
ANTERIOR RADICULOPATHY AND LUPUS ERYTHEMATOSUS CELLS: REPORT OF A CASE. British medical journal, 1964, Sep-26, Volume: 2, Issue:5412 Topics: Cerebrospinal Fluid Proteins; Fluorescent Antibody Technique; Humans; Lupus Erythematosus, Systemic;	1964
PERIPHERAL NEUROPATHY IN RHEUMATOID ARTHRITIS. British medical journal, 1965, May-01, Volume: 1, Issue:5443 Topics: Agglutination; Angiography; Arteritis; Arthritis; Arthritis, Rheumatoid; Brachial Artery; Classifica	1965
[Peripheral neuropathy and myositis in idiopathic hypereosinophilic syndrome: case report]. Arquivos de neuro-psiquiatria, 2004, Volume: 62, Issue:1 Topics: Adult; Anti-Inflammatory Agents; Electromyography; Female; Humans; Hypereosinophilic Syndrome; Myosi	2004
[Behçet's disease associated with peripheral neuropathy]. Revue neurologique, 2005, Volume: 161, Issue:2 Topics: Anti-Inflammatory Agents; Anticonvulsants; Behcet Syndrome; Carbamazepine; Cyclophosphamide; Diarrhe	2005
Peripheral neuropathy associated with chronic natural killer cell lymphocytosis. Journal of the neurological sciences, 2005, May-15, Volume: 232, Issue:1-2 Topics: Action Potentials; Aged; Anti-Inflammatory Agents; Demyelinating Diseases; Female; Humans; Killer Ce	2005
Bilateral isolated phrenic neuropathy causing painless bilateral diaphragmatic paralysis. Neurology, 2005, Nov-08, Volume: 65, Issue:9 Topics: Adult; Aged; Anti-Inflammatory Agents; Autoimmune Diseases of the Nervous System; Brachial Plexus Ne	2005
Roles of protein C, protein S, and antithrombin III in acute leukemia. American journal of hematology, 2006, Volume: 81, Issue:3 Topics: Antineoplastic Combined Chemotherapy Protocols; Antithrombin III; Asparaginase; Cyclophosphamide; Cy	2006
Reversible multifocal conduction block in sarcoid neuropathy. Journal of the peripheral nervous system : JPNS, 2006, Volume: 11, Issue:1 Topics: Aged; Anti-Inflammatory Agents; Demyelinating Diseases; Dermatitis; Electromyography; Female; Humans	2006
Polyneuropathy, organomegaly, endocrinopathy, M protein, skin changes: not always a POEMS syndrome. Haematologica, 2006, Volume: 91, Issue:5 Suppl Topics: Cyclosporine; Diagnostic Errors; Eosinophilia; Fasciitis; Hepatomegaly; Humans; Hyperpigmentation; I	2006
Possible increase of the neurotoxicity of vincristine by the concurrent use of posaconazole in a young adult with leukemia. Journal of pediatric hematology/oncology, 2007, Volume: 29, Issue:2 Topics: Adult; Antifungal Agents; Antineoplastic Agents; Demyelinating Diseases; Electromyography; Fever; Hu	2007
Diagnostic and theraputic challenges. Retina (Philadelphia, Pa.), 2007, Volume: 27, Issue:2 Topics: Administration, Oral; Aged; Alprostadil; Asthma; Churg-Strauss Syndrome; Drug Therapy, Combination;	2007
Pure neural leprosy: steroids prevent neuropathy progression. Arquivos de neuro-psiquiatria, 2007, Volume: 65, Issue:4A Topics: Adult; Aged; Clofazimine; Dapsone; Drug Therapy, Combination; Electrophysiology; Female; Follow-Up S	2007
Recurrent peripheral facial paresis may constitute the sole clinical manifestation in neuro-behcet disease. The neurologist, 2008, Volume: 14, Issue:1 Topics: Adult; Anti-Inflammatory Agents; Behcet Syndrome; Brachial Plexus Neuropathies; Humans; Male; Periph	2008
[Worsening of leprosy lesions in a Philippine-born patient]. Enfermedades infecciosas y microbiologia clinica, 2008, Volume: 26, Issue:2 Topics: Adult; Antigens, Bacterial; Dapsone; Facial Dermatoses; Fever; Humans; Leprostatic Agents; Leprosy,	2008
Polyneuropathy with monoclonal gammopathy: studies of 11 patients. Annals of neurology, 1981, Volume: 10, Issue:1 Topics: Adult; Aged; Biopsy; Cerebrospinal Fluid Proteins; Electromyography; Female; Fluorescent Antibody Te	1981
Neurologic complications of infectious mononucleosis after steroid therapy. Southern medical journal, 1981, Volume: 74, Issue:9 Topics: Adolescent; Brachial Plexus; Encephalitis; Epilepsy, Tonic-Clonic; Female; Humans; Infectious Mononu	1981
The effect of combination therapy (steroids, immunosuppressives, and plasmapheresis) on 5 mixed cryoglobulinemia patients with renal, neurologic, and vascular involvement. Arthritis and rheumatism, 1981, Volume: 24, Issue:9 Topics: Aged; Chlorambucil; Cryoglobulinemia; Female; Humans; Kidney Diseases; Male; Middle Aged; Paraprotei	1981
[Neuropathy in angioimmunoblastic lymphadenopathy (author's transl)]. Revue neurologique, 1981, Volume: 137, Issue:8-9 Topics: Aged; Electromyography; Female; Humans; Hypesthesia; Immunoblastic Lymphadenopathy; Lymph Nodes; Mal	1981
Angiofollicular lymph node hyperplasia and peripheral neuropathy: association with monoclonal gammopathy. Mayo Clinic proceedings, 1982, Volume: 57, Issue:6 Topics: Electrophoresis; Humans; Hypergammaglobulinemia; Hyperplasia; Immunoglobulin G; Lymph Nodes; Male; M	1982
[Popliteal neuritis complicating temporal arteritis]. Harefuah, 1981, Nov-15, Volume: 101, Issue:10 Topics: Aged; Giant Cell Arteritis; Humans; Knee Joint; Neuritis; Peripheral Nervous System Diseases; Predni	1981
Osteosclerotic myeloma and peripheral neuropathy. Neurology, 1983, Volume: 33, Issue:2 Topics: Adult; Aged; Antibodies, Monoclonal; Bone Neoplasms; Female; Humans; Immunoglobulin kappa-Chains; Ma	1983
Digitalgia paresthetica with digital neuropathy in rheumatoid arthritis. Southern medical journal, 1983, Volume: 76, Issue:7 Topics: Adult; Arthritis, Rheumatoid; Female; Fingers; Humans; Male; Middle Aged; Neural Conduction; Neuriti	1983
Lymphoma and leukemia manifested by steroid-responsive polyneuropathy. Archives of neurology, 1983, Volume: 40, Issue:9 Topics: Chronic Disease; Humans; Leukemia, Lymphoid; Lymphatic Diseases; Lymphoma; Male; Middle Aged; Neopla	1983
Treatment of polyneuropathy in Waldenström's macroglobulinemia: role of paraproteinemia and immunologic studies. Neurology, 1983, Volume: 33, Issue:11 Topics: B-Lymphocytes; Chlorambucil; Female; Humans; Immunoglobulin M; Middle Aged; Neurons; Peripheral Nerv	1983
Neurologic abnormalities of Lyme disease: successful treatment with high-dose intravenous penicillin. Annals of internal medicine, 1983, Volume: 99, Issue:6 Topics: Adolescent; Adult; Arthritis, Infectious; Cranial Nerve Diseases; Female; Humans; Immunoglobulin M;	1983
Treatment of ulnar and median nerve function loss in borderline leprosy. Leprosy review, 1984, Volume: 55, Issue:1 Topics: Humans; Leprosy; Median Nerve; Peripheral Nervous System Diseases; Prednisone; Ulnar Nerve	1984
Peripheral neuropathy in osteosclerotic myeloma: clinical and electrodiagnostic improvement with chemotherapy. Muscle & nerve, 1984, Volume: 7, Issue:2 Topics: Adult; Drug Therapy, Combination; Electrodiagnosis; Female; Humans; Melphalan; Multiple Myeloma; Ost	1984
Acquired demyelinative polyneuropathy: diagnosis and treatment with special reference to immunosuppressive therapy. The Nebraska medical journal, 1984, Volume: 69, Issue:3 Topics: Adult; Azathioprine; Demyelinating Diseases; Female; Humans; Immunosuppressive Agents; Male; Middle	1984
Painful lumbosacral plexopathy with elevated erythrocyte sedimentation rate: a treatable inflammatory syndrome. Annals of neurology, 1984, Volume: 15, Issue:5 Topics: Aged; Blood Sedimentation; Cyclophosphamide; Female; Humans; Lumbosacral Plexus; Male; Middle Aged;	1984
Asthma, hypereosinophilia and peripheral neuropathy in a migrant farm worker. Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 1995, Volume: 74, Issue:1 Topics: Adult; Agriculture; Asthma; Diagnosis, Differential; El Salvador; Humans; Hypereosinophilic Syndrome	1995
[Polyneuropathy and testicular seminoma]. Neurologia (Barcelona, Spain), 1995, Volume: 10, Issue:3 Topics: Aged; Biopsy; Humans; Male; Median Nerve; Peripheral Nervous System Diseases; Prednisone; Seminoma;	1995
[Peripheral neuropathy unmasked by therapy with adrenal cortex hormones during myalgia-eosinophilia syndrome related to L-tryptophan]. Presse medicale (Paris, France : 1983), 1994, Jun-25, Volume: 23, Issue:24 Topics: Adult; Eosinophilia-Myalgia Syndrome; Female; Humans; Immunoglobulins, Intravenous; Peripheral Nervo	1994
[Isolated acute peripheral facial paralysis in children. Etiological and prognostic study]. Archives francaises de pediatrie, 1993, Volume: 50, Issue:5 Topics: Acute Disease; Adolescent; Child; Child, Preschool; Facial Paralysis; Female; Humans; Infant; Male;	1993
[Neuropathy caused by necrotizing vasculitis in HIV-1 infection]. Revue neurologique, 1993, Volume: 149, Issue:5 Topics: Adult; HIV Infections; HIV-1; Humans; Male; Peripheral Nervous System Diseases; Prednisone; Vasculit	1993
Corticosteroid responsive puffy hands and occult vasculitic neuropathy: RS3PE plus? The Journal of rheumatology, 1993, Volume: 20, Issue:1 Topics: Aged; Antigen-Antibody Reactions; Edema; Humans; Male; Peripheral Nervous System Diseases; Prednison	1993
Long-term effects of vincristine on the peripheral nervous system. Journal of neuro-oncology, 1993, Volume: 15, Issue:1 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Female;	1993
Combined central and peripheral acute demyelination. Italian journal of neurological sciences, 1993, Volume: 14, Issue:1 Topics: Adult; Brain; Central Nervous System Diseases; Demyelinating Diseases; Electroencephalography; Elect	1993
Neurotoxicity of idiopathic hypereosinophilia on a case with simultaneous CNS and PNS involvement. Italian journal of neurological sciences, 1993, Volume: 14, Issue:3 Topics: Aged; Brain; Central Nervous System Diseases; Eosinophilia; Humans; Magnetic Resonance Imaging; Male	1993
[Neuro-Behçet: a follow-up of 4 cases treated with chlorambucil]. Anales de medicina interna (Madrid, Spain : 1984), 1995, Volume: 12, Issue:12 Topics: Adult; Antineoplastic Agents, Alkylating; Behcet Syndrome; Brain Diseases; Chlorambucil; Drug Therap	1995
[Neuropathy of the common peroneal nerve caused by giant cell arteritis]. Minerva cardioangiologica, 1996, Volume: 44, Issue:11 Topics: Aged; Anti-Inflammatory Agents; Female; Giant Cell Arteritis; Humans; Male; Peripheral Nervous Syste	1996
[Possible role of the immune system in lead peripheral polyneuropathy. Case report]. Arquivos de neuro-psiquiatria, 1997, Volume: 55, Issue:1 Topics: Adult; Glucocorticoids; Humans; Lead Poisoning; Male; Peripheral Nervous System Diseases; Prednisone	1997
Chronic inflammatory demyelinating polyradiculoneuropathy in children: II. Long-term follow-up, with comparison to adults. Muscle & nerve, 1997, Volume: 20, Issue:12 Topics: Adolescent; Adult; Child; Child, Preschool; Chronic Disease; Demyelinating Diseases; Female; Follow-	1997
A case-control and nerve biopsy study of CREST multiple mononeuropathy. Neurology, 1997, Volume: 49, Issue:6 Topics: Aged; Antirheumatic Agents; Biopsy; Case-Control Studies; CREST Syndrome; Disease Progression; Drug	1997
[Clinical judgment and decision making in medical practice. A retiree with fatigue and foot drop]. Nederlands tijdschrift voor geneeskunde, 1998, Jan-24, Volume: 142, Issue:4 Topics: Anti-Inflammatory Agents; Castleman Disease; Diagnosis, Differential; Fatigue; Foot; Humans; Male; M	1998
[Chronic inflammatory demyelinating polyradiculoneuropathy. Study of 18 cases]. Arquivos de neuro-psiquiatria, 1997, Volume: 55, Issue:4 Topics: Adult; Aged; Aged, 80 and over; Child; Chronic Disease; Demyelinating Diseases; Female; Fluorescent	1997
Neuropathy associated with angioimmunoblastic lymphadenopathy-like T-cell lymphoma. Internal medicine (Tokyo, Japan), 1998, Volume: 37, Issue:7 Topics: Aged; Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Dox	1998
Treatment of mononeuropathy multiplex in hepatitis C virus and cryoglobulinemia. Muscle & nerve, 1998, Volume: 21, Issue:11 Topics: Adult; Anti-Inflammatory Agents; Antiviral Agents; Cryoglobulinemia; Female; Hepatitis C; Humans; In	1998
[Polyradiculoneuritis and sarcoidosis]. La Revue de medecine interne, 1998, Volume: 19, Issue:10 Topics: Anti-Inflammatory Agents; Female; Follow-Up Studies; Humans; Magnetic Resonance Imaging; Middle Aged	1998
Successful treatment of HIV-related vasculitis with peripheral neuropathy with short-term steroids followed by the association of zidovudine and plasmapheresis. Transfusion science, 1993, Volume: 14, Issue:4 Topics: Adult; AIDS-Related Opportunistic Infections; Combined Modality Therapy; HIV Seropositivity; Humans;	1993
Myasthenia gravis and peripheral neuropathy in an Amazon indigenous female. Neuromuscular disorders : NMD, 1999, Volume: 9, Issue:4 Topics: Adult; Anti-Inflammatory Agents; Brazil; Female; Humans; Indians, South American; Myasthenia Gravis;	1999
Fibrosing alveolitis predating microscopic polyangiitis. Scandinavian journal of rheumatology, 1999, Volume: 28, Issue:4 Topics: Aged; Glomerulonephritis; Humans; Male; Necrosis; Peripheral Nervous System Diseases; Prednisone; Pu	1999
Persistent paraneoplastic neurologic syndrome after successful therapy of Hodgkin's disease. European journal of haematology, 2001, Volume: 66, Issue:1 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Ataxia; Bleomycin; Combined Modality Therapy;	2001
Therapeutic dilemmas with thalidomide in multiple myeloma: case discussions. Seminars in oncology, 2001, Volume: 28, Issue:6 Topics: Adult; Angiogenesis Inhibitors; Drug Therapy, Combination; Female; Glucocorticoids; Hematopoietic St	2001
Primary malignant lymphoma of the CNS and polyneuropathy in a patient with necrotizing vasculitis treated with immunosuppression. Journal of neurology, 1979, Jan-05, Volume: 220, Issue:4 Topics: Azathioprine; Brain Neoplasms; Female; Humans; Immunosuppressive Agents; Lymphoma; Middle Aged; Necr	1979
Mononeuropathy multiplex as a complication of amphetamine angiitis. Neurology, 1975, Volume: 25, Issue:6 Topics: Adolescent; Barbiturates; Humans; Lysergic Acid Diethylamide; Male; Methamphetamine; Peripheral Nerv	1975
Brachial plexus neuropathy. Association with desensitizing antiallergy injections. JAMA, 1975, Nov-10, Volume: 234, Issue:6 Topics: Allergens; Brachial Plexus; Desensitization, Immunologic; Dust; Female; Humans; Injections, Subcutan	1975
Dapsone-induced motor polyneuropathy. A complication of prolonged treatment of subcorneal pustular dermatosis. Archives of dermatology, 1976, Volume: 112, Issue:8 Topics: Adult; Dapsone; Dose-Response Relationship, Drug; Female; Humans; Motor Neurons; Nerve Degeneration;	1976
Primary amyloidosis, paraproteinaemia and neuropathy. Proceedings of the Royal Society of Medicine, 1976, Volume: 69, Issue:9 Topics: Amyloidosis; Female; Humans; Melphalan; Middle Aged; Paraproteinemias; Peripheral Nervous System Dis	1976
[Polyneuropathy in patients with Hodgkin's disease and acute leukemia treated by the combined cyclic method according to the MOPP and POMP schedules]. Polski tygodnik lekarski (Warsaw, Poland : 1960), 1976, Nov-29, Volume: 31, Issue:48 Topics: Adult; Aged; Antineoplastic Agents; Drug Therapy, Combination; Female; Hodgkin Disease; Humans; Leuk	1976
Chronic lymphatic leukaemia, chlorambucil, and sensorimotor peripheral neuropathy. British medical journal, 1977, Nov-12, Volume: 2, Issue:6097 Topics: Chlorambucil; Humans; Leukemia, Lymphoid; Male; Middle Aged; Peripheral Nervous System Diseases; Pre	1977
Plasmapheresis in chronic demyelinating polyneuropathy. The New England journal of medicine, 1992, Apr-16, Volume: 326, Issue:16 Topics: Adult; Female; Humans; Melphalan; Multiple Myeloma; Peripheral Nervous System Diseases; Plasmapheres	1992
Orofacial complications of chemotherapy for breast cancer. Oral surgery, oral medicine, and oral pathology, 1992, Volume: 74, Issue:2 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Candidiasis, Oral; Chi-Squa	1992
Inflammatory peripheral neuropathy following high dose chemotherapy and autologous bone marrow transplantation. Bone marrow transplantation, 1992, Volume: 10, Issue:3 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Combined Modalit	1992
Asymmetrical weakness in polymyositis associated with neuropathic involvement. Clinical rheumatology, 1991, Volume: 10, Issue:4 Topics: Humans; Male; Middle Aged; Muscles; Myositis; Neural Conduction; Peripheral Nerves; Peripheral Nervo	1991
Corticosteroid-responsive dominantly inherited neuropathy in childhood. Neurology, 1991, Volume: 41, Issue:3 Topics: Child; Child, Preschool; Demyelinating Diseases; Electrodiagnosis; Female; Genes, Dominant; Humans;	1991
Peripheral neuropathy associated with hypereosinophilia. Acta neurologica Belgica, 1991, Volume: 91, Issue:1 Topics: Aged; Eosinophilia; Female; Hand; Humans; Leg; Male; Middle Aged; Neurologic Examination; Paresthesi	1991
Autoimmune pancytopenia following allogeneic bone marrow transplantation. Bone marrow transplantation, 1990, Volume: 6, Issue:6 Topics: Autoimmune Diseases; Bone Marrow Transplantation; Female; Host vs Graft Reaction; Humans; Leukemia,	1990
Peripheral neuropathy associated with the hypereosinophilic syndrome. Archives of physical medicine and rehabilitation, 1990, Volume: 71, Issue:6 Topics: Electromyography; Eosinophilia; Humans; Male; Middle Aged; Neural Conduction; Peripheral Nervous Sys	1990
Meningoencephalitis and peripheral neuropathy complicating adult Still's disease. The Journal of rheumatology, 1990, Volume: 17, Issue:5 Topics: Adult; Arthritis, Juvenile; Aspirin; Female; Humans; Indomethacin; Meningoencephalitis; Peripheral N	1990
Treatment of sensory neuropathy. Neurology, 1990, Volume: 40, Issue:11 Topics: Acute Disease; Humans; Neurons, Afferent; Peripheral Nervous System Diseases; Plasma Exchange; Predn	1990
Treatment of patients with neuropathy and anti-MAG IgM M-proteins. Annals of neurology, 1988, Volume: 24, Issue:1 Topics: Aged; Antineoplastic Agents; Autoantibodies; Blood Proteins; Chlorambucil; Cyclophosphamide; Humans;	1988
Lower extremity peripheral neuropathy and ischemic ulcers associated with giant cell arteritis. The Journal of rheumatology, 1989, Volume: 16, Issue:10 Topics: Foot Diseases; Giant Cell Arteritis; Headache; Humans; Leg; Male; Middle Aged; Peripheral Nervous Sy	1989
Serial evaluation of neuromuscular function in management of chronic inflammatory demyelinating polyneuropathy. A case report. Physical therapy, 1987, Volume: 67, Issue:11 Topics: Activities of Daily Living; Adult; Chronic Disease; Combined Modality Therapy; Cyclophosphamide; Dem	1987
Dapsone-induced peripheral neuropathy. International journal of dermatology, 1986, Volume: 25, Issue:5 Topics: Administration, Oral; Adult; Dapsone; Dermatitis Herpetiformis; Humans; Injections, Intramuscular; M	1986
Effects of Mega-COMLA (cyclophosphamide, cytarabine, vincristine, and methotrexate followed by leucovorin and prednisone) plus CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) in the treatment of lymphoid neoplasms with very poor prognosi Cancer treatment reports, 1986, Volume: 70, Issue:8 Topics: Actuarial Analysis; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; C	1986
Chronic inflammatory demyelinating polyneuropathy of infancy: a corticosteroid-responsive disorder. Annals of neurology, 1986, Volume: 20, Issue:1 Topics: Child, Preschool; Demyelinating Diseases; Female; Humans; Infant; Infant, Newborn; Male; Neural Cond	1986
Neuropathy associated with cryoglobulinemia. Muscle & nerve, 1986, Volume: 9, Issue:7 Topics: Adenocarcinoma; Aged; Antibodies, Antinuclear; Cryoglobulinemia; Humans; Male; Peripheral Nerves; Pe	1986
The clinical spectrum of inflammatory-angiopathic neuropathy. Journal of neurology, neurosurgery, and psychiatry, 1986, Volume: 49, Issue:11 Topics: Adolescent; Adult; Aged; Blood Vessels; Collagen Diseases; Female; Humans; Immunosuppressive Agents;	1986
Successful treatment of peripheral neuropathy with chemotherapy in osteosclerotic myeloma. Journal of neurology, 1987, Volume: 234, Issue:4 Topics: Drug Therapy, Combination; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Neural Conduction	1987
Giant-cell arteritis with peripheral neuropathy. Lancet (London, England), 1968, May-11, Volume: 1, Issue:7550 Topics: Aged; Anemia, Hypochromic; Biopsy; Diagnosis, Differential; Giant Cell Arteritis; Humans; Iron; Male	1968
Sarcoidosis and the acoustic nerve. Archives of otolaryngology (Chicago, Ill. : 1960), 1969, Volume: 90, Issue:3 Topics: Adult; Audiometry; gamma-Globulins; Humans; Immunoglobulin G; Immunoglobulin M; Male; Optic Nerve; P	1969
Monilial septicaemia in acute leukaemia. Successful treatment in a case complicated by acute uric acid nephropathy. The New Zealand medical journal, 1966, Volume: 65, Issue:401 Topics: Acetazolamide; Adolescent; Amphotericin B; Candidiasis; Humans; Infectious Mononucleosis; Kidney Dis	1966
[Neurologic complications of leukemias. Disease of the peripheral nervous system and of the meninges in a clinical case of chronic lymphatic leukemia]. Schweizerische medizinische Wochenschrift, 1968, Volume: 98, Issue:15 Topics: Central Nervous System Diseases; Electromyography; Female; Femoral Nerve; Humans; Leukemia, Lymphoid	1968
The neuropathy of Sjögren's syndrome. Trigeminal nerve involvement. Annals of internal medicine, 1969, Volume: 70, Issue:4 Topics: Adult; Aged; Blood Cell Count; Blood Sedimentation; Cranial Nerves; Electromyography; Female; Humans	1969
Remarkable recovery of a steroid-responsive recurrent polyneuropathy. Journal of neurology, neurosurgery, and psychiatry, 1970, Volume: 33, Issue:1 Topics: Biopsy; Child; Chloroquine; Demyelinating Diseases; Electromyography; Female; Humans; Locomotion; Mu	1970
Familial brachial neuropathy. Two case reports with discussion. Neurology, 1971, Volume: 21, Issue:9 Topics: Adolescent; Arm; Brachial Plexus; Follow-Up Studies; Humans; Male; Muscular Diseases; Neural Conduct	1971
[Principles and limits of ACTH-cortisone therapy in neurology]. Bibliotheca psychiatrica et neurologica, 1969, Volume: 139 Topics: Adrenal Cortex Hormones; Adrenocorticotropic Hormone; Cortisone; Dexamethasone; Epilepsy; Facial Par	1969
Optic nerve sarcoidosis. Report of a case. Archives of ophthalmology (Chicago, Ill. : 1960), 1972, Volume: 87, Issue:3 Topics: Adult; Diagnosis, Differential; Female; Granuloma; Humans; Ophthalmoscopy; Optic Atrophy; Optic Nerv	1972
Combination chemotherapy in the treatment of advanced Hodgkin's disease. South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde, 1973, Jun-02, Volume: 47, Issue:21 Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Benzoates; Female; Hodgkin Disease; Humans; Leukopen	1973
Optic neuropathy of Graves disease, hyperthyroidism, and ocular myasthenia gravis. Archives of ophthalmology (Chicago, Ill. : 1960), 1973, Volume: 90, Issue:2 Topics: Adult; Eye Diseases; Graves Disease; Humans; Hyperthyroidism; Male; Myasthenia Gravis; Optic Nerve;	1973
Vincristine neurotoxicity and abnormal secretion of antidiuretic hormone. Archives of internal medicine, 1973, Volume: 132, Issue:5 Topics: Adolescent; Adult; Arginine; Blood; Carcinoma, Small Cell; Cyclophosphamide; Humans; Leukemia, Lymph	1973
Unusual complications of iophendylate injection myelography. Report of a case and review. Archives of neurology, 1973, Volume: 29, Issue:6 Topics: Adult; Drug Hypersensitivity; Female; Follow-Up Studies; Humans; Iodized Oil; Myelography; Optic Ner	1973
A case of rheumatoid arthritis with polyarteritis demonstrated at the Postgraduate Medical School of London. British medical journal, 1966, Apr-23, Volume: 1, Issue:5494 Topics: Angiography; Arthritis, Rheumatoid; Diagnosis, Differential; Electrophoresis; Humans; Male; Middle A	1966

prednisone and Peripheral Nerve Diseases